

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/FC037EC74FE9EN.html>

Date: October 2022

Pages: 53

Price: US\$ 3,500.00 (Single User License)

ID: FC037EC74FE9EN

Abstracts

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Basic fibroblast growth factor also known as bFGF or FGF2 is a member of the fibroblast growth factor family. This protein plays an important role in diverse biological processes, such as limb and nervous system development, wound healing, and tumor growth. Diseases associated with FGF2 include corneal neovascularization and pulmonary capillary hemangiomatosis.

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) pipeline Target constitutes close to 8 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II stages are 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology, Metabolic Disorders, Ophthalmology, Cardiovascular, Central Nervous System, Dermatology, Immunology, Infectious Disease, Musculoskeletal Disorders and Respiratory which include indications Melanoma, Wet (Neovascular/Exudative) Macular Degeneration, Achondroplasia, Bone Disorders, Cancer Pain, Choroidal

Neovascularization, Coronavirus Disease 2019 (COVID-19), Critical Limb Ischemia, Dengue Fever, Diabetic Foot Ulcers, Diabetic Macular Edema, Hepatocellular Carcinoma, Idiopathic Pulmonary Fibrosis, Intermittent Claudication, Lung Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Non-Proliferative Diabetic Retinopathy (NPDR), Non-Small Cell Lung Cancer, Osteoporosis, Pancreatic Cancer, Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD), Peripheral Artery Occlusive Disease (PAOD), Pressure Ulcers, Rheumatoid Arthritis, Solid Tumor and Venous Leg Ulcers (Crural Ulcer).

The latest report *Fibroblast Growth Factor 2 - Drugs In Development, 2022*, outlays comprehensive information on the Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2)

The report reviews Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development

ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics and enlists all their major and minor projects

The report assesses Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Overview

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Companies Involved in Therapeutics Development

Aurealis Therapeutics AG

ID Pharma Co Ltd

RemeGen Co Ltd

Ribomic Inc

Zucero Therapeutics Ltd

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Drug Profiles

AUP-16 - Drug Profile

Product Description

Mechanism Of Action

History of Events

DVC-10101 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Fusion Protein to Inhibit FGF-2 for Cancer - Drug Profile

Product Description

Mechanism Of Action

Oncolytic Virus to Activate FGF2 for Pancreatic Cancer - Drug Profile

Product Description

Mechanism Of Action

pixatimod - Drug Profile

Product Description

Mechanism Of Action

History of Events

RBM-007 - Drug Profile

Product Description

Mechanism Of Action

History of Events

RC-28 - Drug Profile

Product Description

Mechanism Of Action

History of Events

TR-764 - Drug Profile

Product Description

Mechanism Of Action

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Dormant Products

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Discontinued Products

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Product Development Milestones

Featured News & Press Releases

Apr 19, 2022: RIBOMIC announces completion of IND submission for an observational study for continuous phase 2 trial of RBM-007 for treatment of Achondroplasia

Mar 23, 2022: RIBOMIC provides update on RBM-007 program in wet age-related macular degeneration

Dec 28, 2021: RIBOMIC announces preliminary topline data from phase 2 trials of RBM-007 for wet age-related macular degeneration

Nov 15, 2021: RIBOMIC announces RBM-007 phase 1 clinical trial results for achondroplasia

Sep 30, 2021: RIBOMIC announces presentation of masked preliminary interim data from phase 2 trials of RBM-007 for wet age-related macular degeneration at the Retina Society 2021 Meeting

Aug 30, 2021: RIBOMIC completes patient enrollment of its US phase 2 open-label extension clinical trial of RBM-007 for wet age-related macular degeneration (RAMEN Study)

Aug 05, 2021: RIBOMIC completes patient enrollment of its US phase 2 clinical trial of

RBM-007 for wet age-related macular degeneration (TOFU Study)

Jul 12, 2021: RIBOMIC announces first patient dosed in an investigator sponsored trial of RBM007 in treatment naïve wet AMD patients

May 12, 2021: RIBOMIC announces completion of its phase I trial of RBM-007 for the treatment of achondroplasia

May 06, 2021: RIBOMIC announces publication of research paper on aptamer drug discovery for achondroplasia

Feb 01, 2021: Ribomic announces completion of 50% of enrollment of its phase 2 clinical trial for wet age-related macular degeneration (TOFU study)

Nov 11, 2020: RIBOMIC announces initiation of RAMEN open-label extension clinical trial for RBM007 in wet AMD patients

Jul 15, 2020: RIBOMIC announces dosing of first subject in RBM-007 phase 1 clinical trial for Achondroplasia

May 11, 2020: Safe-to-proceed under IND to initiate clinical trials of RBM-007 for treatment of achondroplasia

May 07, 2020: RIBOMIC resumes trial recruitment suspended by coronavirus

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Aurealis Therapeutics AG, 2022
Pipeline by ID Pharma Co Ltd, 2022
Pipeline by RemeGen Co Ltd, 2022
Pipeline by Ribomic Inc, 2022
Pipeline by Zucero Therapeutics Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/FC037EC74FE9EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/FC037EC74FE9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970